Business
Incyte Corporation (INCY) Discusses mutCALR Data and Therapeutic Advances in Myeloproliferative Neoplasms at ASH Transcript
Conference Call Participants
Claire Harrison
John Mascarenhas
Bethan Psaila
Brian Abrahams – RBC Capital Markets, Research Division
Erik Lavington – Mizuho Securities USA LLC, Research Division
Michael Schmidt – Guggenheim Securities, LLC, Research Division
Srikripa Devarakonda – Truist Securities, Inc., Research Division
Tazeen Ahmad – BofA Securities, Research Division
Gavin Clark-Gartner – Evercore ISI Institutional Equities, Research Division
Marc Frahm – TD Cowen, Research Division
Ashwani Verma – UBS Investment Bank, Research Division
James Shin – Deutsche Bank AG, Research Division
Reni Benjamin – Citizens JMP Securities, LLC, Research Division
Etzer Darout – Barclays Bank PLC, Research Division
Matthew Phipps – William Blair & Company L.L.C., Research Division
Imogen Mansfield – Cantor Fitzgerald & Co., Research Division
Stephen Willey – Stifel, Nicolaus & Company, Incorporated, Research Division
Presentation
Pablo Cagnoni
President and Head of Research & Development
Okay. Good morning, everyone, and welcome. Welcome those of you here at — in Orlando at ASH, and welcome those at the webcast. Apologies for the late start. We had to adhere to certain guidelines from ASH, and there was no way to schedule this. And 2 of our speakers were busy presenting actually scientific data at the meeting. So we were forced to start a little bit late. So thank you for your patience. I’m sure you had an opportunity to grab some lunch. We’re going to spend the next 45 minutes or so reviewing data from our 989. We’re going to call it 989 for short program with you. I think this data, some of it was presented in June of this year at AHA in patients with ET. And yesterday and today, you heard from 2 of our speakers today about the translational data and the data in MF. We think this is a really important
